Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.2K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.5K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.5K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.8K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.8K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.5K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.5K
Production of Formed Elements01:34

Production of Formed Elements

5.1K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
5.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.

Cancer medicine·2026
Same author

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.

The Journal of experimental medicine·2026
Same author

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Blood cancer journal·2026
Same author

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Nature biomedical engineering·2026
Same author

Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma.

Blood advances·2026

Related Experiment Video

Updated: Mar 1, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.2K

Hematologic Malignancies: Plasma Cell Disorders.

Madhav V Dhodapkar1, Ivan Borrello1, Adam D Cohen1

  • 1From Yale University, New Haven, CT; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 1, 2017
PubMed
Summary
This summary is machine-generated.

New immunotherapies, including monoclonal antibodies and CAR T-cell therapies targeting BCMA, show promise for treating relapsed/refractory multiple myeloma (MM). These advanced treatments offer improved survival and high response rates by directly attacking cancer cells and enhancing immune responses against MM.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K

Related Experiment Videos

Last Updated: Mar 1, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.2K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) is a bone marrow malignancy with complex tumor microenvironment interactions.
  • Current MM therapies face challenges in overcoming resistance and relapse.

Purpose of the Study:

  • To review emerging immunotherapeutic strategies for multiple myeloma.
  • To highlight the potential of monoclonal antibodies and cellular immunotherapies.

Main Methods:

  • Review of clinical trial data and scientific literature on MM immunotherapies.
  • Analysis of novel therapeutic targets including CD38, SLAMF7, and BCMA.
  • Evaluation of chimeric antigen receptor (CAR) T-cell therapy approaches.

Main Results:

  • Monoclonal antibodies like daratumumab and elotuzumab demonstrate high response rates in relapsed/refractory MM.
  • CAR T-cell therapies, particularly those targeting BCMA, show dramatic efficacy in heavily pretreated patients.
  • Toxicity, including cytokine release syndrome and neurotoxicity, is associated with CAR T-cell efficacy.

Conclusions:

  • Immunotherapy represents a significant advancement in MM treatment, offering new hope for patients with refractory disease.
  • Further research is crucial to optimize CAR T-cell therapy, mitigate toxicity, and identify predictive biomarkers for response.